Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00492726
Other study ID # 11976
Secondary ID 2006-000874-56
Status Completed
Phase Phase 3
First received June 26, 2007
Last updated November 3, 2014
Start date July 2006
Est. completion date February 2009

Study information

Verified date November 2014
Source Bayer
Contact n/a
Is FDA regulated No
Health authority Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Study type Interventional

Clinical Trial Summary

A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.


Recruitment information / eligibility

Status Completed
Enrollment 804
Est. completion date February 2009
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Hospitalized men or women >/=18 years of age

- Expected duration of treatment with intravenous antibiotics anticipated to be >/= 5 full days but not exceeding 14 days

- Ability to provide documented and signed written informed consent

- Confirmed or suspected intra abdominal infection defined as follows:

- For a confirmed intra abdominal infection, a surgical procedure (laparotomy or laparoscopy) must have been performed within 24 hours prior to enrollment and reveal at least one of the following:

- Gross peritoneal inflammation with purulent exudates (i.e. peritonitis)

- Intra abdominal abscess

- Macroscopic intestinal perforation with localized or diffuse peritonitis

- Subjects enrolled on the basis of a suspected intra abdominal infection must have:

- Radiological evidence [abdominal plain films, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound] of gastrointestinal perforation or intra-abdominal abscess and the following signs and symptoms:

- Symptoms referable to the abdominal cavity (e.g. anorexia, nausea, vomiting or pain), lasting for at least 24 hours

- Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity

- At least two of the following SIRS criteria:

- Temperature > 38.0°C rectal or tympanic membrane, or temperature < 36.0°C rectal or tympanic

- Heart rate > 90/min

- Respiratory rate > 20/min

- WBC >12,000 cells/mm3 or < 4,000 cells/ mm3

- The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) within 24 hours of enrollment of the study

Exclusion Criteria:

- Known hypersensitivity to quinolones, and/or to carbapenems and/or to any other type of beta lactam antibiotic drugs (e.g. penicillins or cephalosporins), or any of the excipients

- Women who are pregnant or lactating or in whom pregnancy cannot be excluded

- History of tendon disease/disorder related to quinolone treatment

- Known congenital or documented acquired QT prolongation; uncorrected hypokalemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left ventricular ejection fraction; previous history of symptomatic arrhythmias

- Concomitant use of any of the following drugs, reported to increase the QT interval: antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) or antiarrhythmics class III (e.g., amiodarone, sotalol, dofetilide, ibutilide), neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressive agents, certain antimicrobials (sparfloxacin, erythromycin IV, pentamidine, antimalarials, particularly halofantrine), certain antihistaminics (terfenadine, astemizole, mizolastine), and others (cisapride, vincamine IV, bepridil, diphemanil)

- Known severe end stage liver disease

- Creatinine clearance </= 30 mL/min/1.73 m2

- Systemic antibacterial therapy administered for more than 24 hours within 7 days of enrollment

- Need for systemic antibacterial therapy with agents other than those described in the study protocol

- Indwelling peritoneal catheter

- Pre existing ascites and presumed spontaneous bacterial peritonitis

- Perforation of the stomach or duodenum, if the duration of perforation is less than 24 hours or if operated on within 24 hours of perforation

- Perforation of the small bowel (excluding the duodenum) or large bowel, if the duration of perforation is less than 12 hours or if operated on within 12 hours of perforation

- All pancreatic processes including pancreatic sepsis, peri-pancreatic sepsis, or an intra abdominal infection secondary to pancreatitis

- Liver and splenic abscess

- Transmural bowel ischemia or necrosis without perforation or established peritonitis or abscess

- Acute and gangrenous cholecystitis without perforation

- Acute cholangitis

- Early acute, suppurative, or gangrenous non-perforated appendicitis

- Subjects requiring antibiotic irrigations of the abdominal cavity or surgical wound

- Treatment with "open abdomen" or marsupialization, or multiple planned re laparotomies

- Infections originating from the female genital tract

- Peri-nephric infections

- Evidence of sepsis with shock requiring the administration of vasopressors for more than 4 consecutive hours

- Known rapidly fatal underlying disease (death expected within 6 months)

- Neutropenia (neutrophil count < 1,000/mL) caused by immunosuppressive therapy or malignancy

- Receiving chronic treatment with known immunosuppressant therapy (including chronic treatment with > 15 mg/day of systemic prednisone or equivalent)

- Subjects known to have AIDS (CD4 count < 200/mL) or HIV seropositives who are receiving HAART (HIV positive subjects may be included. HIV testing is not required for this study protocol)

- Subjects with a malignant or pre malignant hematological condition, including Hodgkin's disease and non-Hodgkin lymphoma (subjects with solid tumor can be included in the study)

- Subjects with a Body Mass Index >/= 45 kg/m2

- Previous enrollment in this study

- Participation in any clinical investigational drug study within the previous 4 weeks

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Moxifloxacin (Avelox, BAY12-8039)
Moxifloxacin, 400mg, administered intravenously once daily
Ertapenem intravenous
Active treatment: Ertapenem 1.0g, administered intravenously once daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

Argentina,  Belgium,  Bulgaria,  Estonia,  France,  Germany,  Greece,  Israel,  Latvia,  Lithuania,  Romania,  Russian Federation,  South Africa,  Spain, 

References & Publications (1)

De Waele JJ, Tellado JM, Alder J, Reimnitz P, Jensen M, Hampel B, Arvis P. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents. 2013 Jan;41(1):57-64. d — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC. 21 to 28 days after completion of study drug therapy No
Secondary Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered. During treatment at day 5 +/- 1 day No
Secondary Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s) Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'. During treatment at day 5 +/- 1 day No
Secondary Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered. after 5 - 14 days of therapy No
Secondary Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s) Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'. After 5 - 14 days of therapy No
Secondary Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s) Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC. 21 - 28 days after end of therapy No
Secondary Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s) Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC. 21 - 28 days after end of therapy No
Secondary Number of Subjects Who Died Due to Intra-abdominal Infections Number of subjects who had died due to intra abdominal infections by the time of TOC visit. 21 - 28 days after end of treatment at TOC Visit No
Secondary Duration of Hospitalization Duration of hospitalization in the per protocol population. From the first admission date to the discharge date (from 4 to 71 days after start of study medication) No
Secondary Duration of Hospitalization Postoperatively Duration of hospitalization after the first surgery until discharge in the per protocol population. Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication) No
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A